Search

everythinglearnresearchcommunity

for

Search:↓

Topical spironolactone is gaining attention as an alternative hair loss treatment, but it's not as effective as other options like finasteride. Oral spironolactone can cause side effects in men, and there are better topical alternatives like RU, Pyril, and CB.

Spearmint tea and inositol are discussed as potential treatments for hair regrowth, but their effectiveness is questioned. Alternatives like green tea, MSM, and evening primrose oil are suggested for hair health.

The user is using oral Minoxidil, oral Dutasteride, microneedling, and RU58841 for hair loss, noticing slow progress with small hairs appearing. They are inconsistent with microneedling frequency, sometimes doing it weekly or skipping weeks.

An 18-year-old is seeking advice on their hair loss pattern and potential treatments. They are considering using Minoxidil, finasteride, and RU58841.

A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.

RU58841 was ineffective for OP, who is considering adding KX-826 with finasteride. User8 suggests KX-826 may help when combined with minoxidil and dutasteride.

The user experienced significant hair regrowth using dutasteride (0.5 mg three times a week) and RU58841 (5% once a day), with no side effects reported from RU58841. They are considering increasing the RU58841 dose or adding minoxidil for further improvement.

This post and conversation are about mocking hair loss treatments, specifically Minoxidil, finasteride, and RU58841, with humorous and sarcastic comments. The satire suggests absurd methods and results, highlighting skepticism about these treatments.

Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.

27-year-old female experiences aggressive hair thinning and hirsutism despite normal testosterone levels. Spironolactone and 2% minoxidil were ineffective; high DHEA sulfate levels may be the cause.

The user is considering stopping RU58841 due to inconvenience and potential side effects, while continuing with oral minoxidil and dutasteride. Another user shared their experience of stopping RU58841 without significant hair shedding while on dutasteride and minoxidil.

Using RU58841 and topical minoxidil together is fine and does not cancel out the benefits of each. Applying both treatments consecutively is acceptable.

The user documented hair regrowth progress over 8 weeks using Minoxidil foam twice daily and weekly microneedling. Another user suggested adding finasteride for better results.

Topical spiro's effectiveness on androgens is discussed. User tried oral DUT, oral Min, keto/nizoral, and RU but experienced worsening hair loss and chest pains. Suggestion given to increase dutasteride and oral minoxidil dosage before considering spironolactone.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

The conversation discusses an 8.5-month progress of using Minoxidil, Finasteride, and RU58841 for hair loss. People are complimenting the user on the significant improvement in hair thickness.

A user ordered Alpha Plus from Anagenica, expecting it to contain specific percentages of Fin, Estradiol, Minoxidil, and CB0301. However, the received product's label showed different percentages, including a surprising 25% CB, leading the user to question its safety and accuracy.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

Nanoxidil is considered by some as a substitute for Minoxidil, but users report it as ineffective and expensive. Finasteride is recommended as a more effective treatment, often used with Minoxidil, microneedling, and ketoconazole.

The conversation is about the safety of using a product with azelaic acid and other ingredients on a receding scalp for hair loss. Specific treatments mentioned are Minoxidil, finasteride, and RU58841.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

The user has been using finasteride for almost two years but is considering switching to dutasteride and is curious about adding RU58841. They decide to stick with dutasteride due to concerns about RU58841's safety.

Pyrilitamide (KX-826) did not show significant improvement in hair count compared to placebo after 6 months. It's unclear if it can maintain hair at baseline.

The user is struggling to find a reliable source to buy Kirkland Minoxidil in Canada, expressing concerns about the legitimacy of online sellers. They mention skepticism about websites like Kirkland Minoxidil Solution and Zecoya.

Apply minoxidil at least 1-2 hours before bed to ensure it dries and doesn't transfer to the pillow. Foam dries faster than liquid, and using a satin beanie after drying can help prevent transfer.

A female user's experience using Spironolactone to treat Female Pattern Hair Loss (FPHL) and Androgenic Alopecia, as well as discussing the effectiveness of the drug at different dosages.

Hair loss discussion includes treatments Min, Fin, and RU. Kintor's KX-826 Phase 2 data release delayed to September due to COVID.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.